Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

HG Eichler, E Abadie, A Breckenridge… - Nature reviews Drug …, 2011 - nature.com
Drug regulatory agencies should ensure that the benefits of drugs outweigh their risks, but
licensed medicines sometimes do not perform as expected in everyday clinical practice. …

Adaptive licensing: taking the next step in the evolution of drug approval

HG Eichler, K Oye, LG Baird, E Abadie… - Clinical …, 2012 - Wiley Online Library
Traditional drug licensing approaches are based on binary decisions. At the moment of
licensing, an experimental therapy is presumptively transformed into a fully vetted, safe, …

Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma

HG Eichler, F Pignatti, B Flamion, H Leufkens… - Nature Reviews Drug …, 2008 - nature.com
Drug regulatory agencies are increasingly pressed by the challenge of finding the
appropriate balance between the need for rapid access to new drugs and the need to ensure …

Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue

S Kern, H Eichler, J Stoeve, H Klüter, K Bieback - Stem cells, 2006 - academic.oup.com
Mesenchymal stem cells (MSCs) represent a promising tool for new clinical concepts in
supporting cellular therapy. Bone marrow (BM) was the first source reported to contain MSCs. …

[BOOK][B] Laser-induced dynamic gratings

HJ Eichler, P Günter, DW Pohl - 2013 - books.google.com
… The latter was first used by Eichler and co-workers in 1972 [1.19] to determine heat diffusivities
in ruby and glycerol. Independently, Pohl and co-workers [1.20] developed FRS as an …

Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood

K Bieback, S Kern, H Klüter, H Eichler - Stem cells, 2004 - academic.oup.com
Evidence has emerged that mesenchymal stem cells (MSCs) represent a promising population
for supporting new clinical concepts in cellular therapy. However, attempts to isolate …

Use of cost‐effectiveness analysis in health‐care resource allocation decision‐making: how are cost‐effectiveness thresholds expected to emerge?

HG Eichler, SX Kong, WC Gerth, P Mavros… - Value in …, 2004 - Wiley Online Library
Background: An increasing number of health‐care systems, both public and private, such as
managed‐care organizations, are adopting results from cost‐effectiveness (CE) analysis as …

Autologous concentrated platelet-rich plasma (cPRP) for local application in bone regeneration

A Dugrillon, H Eichler, S Kern, H Klüter - International journal of oral and …, 2002 - Elsevier
Platelets are rich in growth factors that may contribute to an accelerated tissue regeneration
process. The therapeutic osteogenic effect of local platelet administration probably depends …

[HTML][HTML] Good practices for real‐world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR‐ISPE Special Task Force on …

ML Berger, H Sox, RJ Willke, DL Brixner, HG Eichler… - Value in Health, 2017 - Elsevier
Purpose Real‐world evidence (RWE) includes data from retrospective or prospective
observational studies and observational registries and provides insights beyond those addressed …

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

…, M Müller, K Wolff, HG Eichler, H Pehamberger - Nature medicine, 1998 - nature.com
… oligonucleotides for 4 h in the presence of Lipofectin (Gibco BRL, Gaithersburg, MD). A
second incubation was performed 24 h later. Cell extracts were prepared 24 h after the second …